Vault-13

STEMPOINT CAPITAL LP

NEW YORK, NY · CIK 1952142 · 13F filing filed 2024-08-13

SEC-registered investment adviser since 2022 · limited partnership

As an employer

$339.9m reported value -9.2% vs Q1 2024
42positions
55.4%in top 10
16 new 14 added 10 reduced 19 sold out vs Q1 2024

Options: 1 call positions ($350.0k notional), 0 put positions (— notional) – listed below, not included above.

Holdings, Q2 2024

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 SYNDAX PHARMACEUTICALS INC COM SNDX SNDX 1,412,176 $29.0m8.53% 8.53% AddedShares held: Q3 2023 —, Q4 2023 1.1m, Q1 2024 1.1m, Q2 2024 1.4m +311.2k +311,188 28.3%
2 ROIVANT SCIENCES LTD SHS ROIV ROIV 2,712,741 $28.7m8.44% 8.44% ReducedShares held: Q3 2023 —, Q4 2023 2.2m, Q1 2024 3.6m, Q2 2024 2.7m -841.1k -841,103 -23.7%
3 IMMUNOVANT INC COM IMVT IMVT 1,011,879 $26.7m7.86% 7.86% AddedShares held: Q3 2023 —, Q4 2023 322.0k, Q1 2024 627.2k, Q2 2024 1.0m +384.7k +384,651 61.3%
4 CRINETICS PHARMACEUTICALS IN COM CRNX CRNX 551,095 $24.7m7.26% 7.26% ReducedShares held: Q3 2023 —, Q4 2023 249.6k, Q1 2024 619.8k, Q2 2024 551.1k -68.7k -68,694 -11.1%
5 MERUS N V COM MRUS MRUS 288,668 $17.1m5.02% 5.02% AddedShares held: Q3 2023 —, Q4 2023 501.8k, Q1 2024 233.9k, Q2 2024 288.7k +54.8k +54,797 23.4%
6 ARCELLX INC COMMON STOCK ACLX ACLX 280,709 $15.5m4.56% 4.56% AddedShares held: Q3 2023 —, Q4 2023 313.6k, Q1 2024 140.3k, Q2 2024 280.7k +140.4k +140,442 100.1%
7 AMICUS THERAPEUTICS INC COM FOLD FOLD 1,495,047 $14.8m4.36% 4.36% ReducedShares held: Q3 2023 —, Q4 2023 862.8k, Q1 2024 1.5m, Q2 2024 1.5m -52.1k -52,094 -3.4%
8 IMMUNOCORE HLDGS PLC ADS IMCR IMCR 339,351 $11.5m3.38% 3.38% NewShares held: Q3 2023 —, Q4 2023 0, Q1 2024 0, Q2 2024 339.4k
9 APPLIED THERAPEUTICS INC COM APLT APLT 2,211,320 $10.3m3.04% 3.04% AddedShares held: Q3 2023 —, Q4 2023 907.2k, Q1 2024 2.0m, Q2 2024 2.2m +194.3k +194,304 9.6%
10 MERCK & CO INC COM MRK MRK 81,508 $10.2m2.99% 2.99% NewShares held: Q3 2023 —, Q4 2023 89.0k, Q1 2024 0, Q2 2024 81.5k
11 GSK PLC SPONSORED ADR GSK GSK 245,933 $9.5m2.79% 2.79% NewShares held: Q3 2023 —, Q4 2023 0, Q1 2024 0, Q2 2024 245.9k
12 AUTOLUS THERAPEUTICS PLC SPON ADS AUTL AUTL 2,662,732 $9.3m2.73% 2.73% ReducedShares held: Q3 2023 —, Q4 2023 451.4k, Q1 2024 3.0m, Q2 2024 2.7m -303.0k -302,989 -10.2%
13 ARCUTIS BIOTHERAPEUTICS INC COM ARQT ARQT 965,392 $9.0m2.64% 2.64% ReducedShares held: Q3 2023 —, Q4 2023 2.6m, Q1 2024 2.2m, Q2 2024 965.4k -1.2m -1,240,507 -56.2%
14 CABALETTA BIO INC COM CABA CABA 1,178,105 $8.8m2.59% 2.59% AddedShares held: Q3 2023 —, Q4 2023 450.7k, Q1 2024 1.0m, Q2 2024 1.2m +174.2k +174,189 17.4%
15 KALVISTA PHARMACEUTICALS INC COM KALV KALV 736,765 $8.7m2.55% 2.55% ReducedShares held: Q3 2023 —, Q4 2023 423.2k, Q1 2024 1.2m, Q2 2024 736.8k -424.3k -424,295 -36.5%
16 BIOHAVEN LTD COM BHVN BHVN 233,255 $8.1m2.38% 2.38% AddedShares held: Q3 2023 —, Q4 2023 111.4k, Q1 2024 83.5k, Q2 2024 233.3k +149.8k +149,794 179.5%
17 VISTAGEN THERAPEUTICS INC COM VTGN VTGN 1,848,582 $5.8m1.72% 1.72% UnchangedShares held: Q3 2023 —, Q4 2023 1.8m, Q1 2024 1.8m, Q2 2024 1.8m
18 IMMATICS N.V SHS IMTX IMTX 502,207 $5.8m1.72% 1.72% AddedShares held: Q3 2023 —, Q4 2023 1.0m, Q1 2024 491.9k, Q2 2024 502.2k +10.3k +10,281 2.1%
19 DENALI THERAPEUTICS INC COM DNLI DNLI 251,010 $5.8m1.71% 1.71% NewShares held: Q3 2023 —, Q4 2023 0, Q1 2024 0, Q2 2024 251.0k
20 INSMED INC COM PAR $.01 INSM INSM 86,980 $5.8m1.71% 1.71% ReducedShares held: Q3 2023 —, Q4 2023 173.6k, Q1 2024 272.4k, Q2 2024 87.0k -185.5k -185,468 -68.1%
21 CELLDEX THERAPEUTICS INC NEW COM NEW CLDX CLDX 144,467 $5.3m1.57% 1.57% NewShares held: Q3 2023 —, Q4 2023 0, Q1 2024 0, Q2 2024 144.5k
22 LARIMAR THERAPEUTICS INC COM LRMR LRMR 704,349 $5.1m1.50% 1.50% ReducedShares held: Q3 2023 —, Q4 2023 783.2k, Q1 2024 740.9k, Q2 2024 704.3k -36.5k -36,528 -4.9%
23 TSCAN THERAPEUTICS INC COM TCRX TCRX 845,069 $4.9m1.45% 1.45% NewShares held: Q3 2023 —, Q4 2023 0, Q1 2024 0, Q2 2024 845.1k
24 EDGEWISE THERAPEUTICS INC COM EWTX EWTX 271,057 $4.9m1.44% 1.44% NewShares held: Q3 2023 —, Q4 2023 0, Q1 2024 0, Q2 2024 271.1k
25 CORBUS PHARMACEUTICALS HLDGS COM NEW CRBP CRBP 101,479 $4.6m1.35% 1.35% NewShares held: Q3 2023 —, Q4 2023 0, Q1 2024 0, Q2 2024 101.5k
26 FULCRUM THERAPEUTICS INC COM FULC FULC 696,464 $4.3m1.27% 1.27% AddedShares held: Q3 2023 —, Q4 2023 376.6k, Q1 2024 407.1k, Q2 2024 696.5k +289.4k +289,356 71.1%
27 NURIX THERAPEUTICS INC COM NRIX NRIX 203,273 $4.2m1.25% 1.25% NewShares held: Q3 2023 —, Q4 2023 0, Q1 2024 0, Q2 2024 203.3k
28 PYXIS ONCOLOGY INC COMMON STOCK PYXS PYXS 1,202,675 $4.0m1.17% 1.17% ReducedShares held: Q3 2023 —, Q4 2023 0, Q1 2024 1.8m, Q2 2024 1.2m -591.5k -591,520 -33.0%
29 JANUX THERAPEUTICS INC COM JANX JANX 92,949 $3.9m1.15% 1.15% ReducedShares held: Q3 2023 —, Q4 2023 0, Q1 2024 121.6k, Q2 2024 92.9k -28.7k -28,693 -23.6%
30 IDEAYA BIOSCIENCES INC COM IDYA IDYA 101,787 $3.6m1.05% 1.05% AddedShares held: Q3 2023 —, Q4 2023 0, Q1 2024 87.4k, Q2 2024 101.8k +14.4k +14,394 16.5%
31 SPYRE THERAPEUTICS INC COM NEW SYRE SYRE 150,450 $3.5m1.04% 1.04% AddedShares held: Q3 2023 —, Q4 2023 378.8k, Q1 2024 62.3k, Q2 2024 150.4k +88.2k +88,197 141.7%
32 PERSPECTIVE THERAPEUTICS INC COM NEW CATX CATX 343,810 $3.4m1.01% 1.01% NewShares held: Q3 2023 —, Q4 2023 0, Q1 2024 0, Q2 2024 343.8k
33 JASPER THERAPEUTICS INC COM NEW JSPR JSPR 143,775 $3.3m0.96% 0.96% AddedShares held: Q3 2023 —, Q4 2023 0, Q1 2024 129.2k, Q2 2024 143.8k +14.6k +14,564 11.3%
34 BLACK DIAMOND THERAPEUTICS I COM BDTX BDTX 674,198 $3.1m0.92% 0.92% NewShares held: Q3 2023 —, Q4 2023 0, Q1 2024 0, Q2 2024 674.2k
35 VIGIL NEUROSCIENCE INC COM VIGL VIGL 744,412 $3.0m0.88% 0.88% NewShares held: Q3 2023 —, Q4 2023 0, Q1 2024 0, Q2 2024 744.4k
36 NEUROGENE INC COM NGNE NGNE 78,601 $2.9m0.84% 0.84% NewShares held: Q3 2023 —, Q4 2023 0, Q1 2024 0, Q2 2024 78.6k
37 SILENCE THERAPEUTICS PLC ADS SLN SLN 124,866 $2.4m0.70% 0.70% NewShares held: Q3 2023 —, Q4 2023 0, Q1 2024 0, Q2 2024 124.9k
38 PROTARA THERAPEUTICS INC COM STK TARA TARA 984,113 $2.0m0.60% 0.60% AddedShares held: Q3 2023 —, Q4 2023 0, Q1 2024 168.4k, Q2 2024 984.1k +815.7k +815,671 484.2%
39 HELIX ACQUISITION CORP II CL A ORD SHS BBOT BBOT 200,000 $2.0m0.60% 0.60% UnchangedShares held: Q3 2023 —, Q4 2023 0, Q1 2024 200.0k, Q2 2024 200.0k
40 SURROZEN INC COM NEW SRZN SRZN 143,510 $1.6m0.46% 0.46% NewShares held: Q3 2023 —, Q4 2023 0, Q1 2024 0, Q2 2024 143.5k
41 PERCEPTIVE CAP SOLUTIONS COR CL A ORD SHS FRNM FRNM 150,000 $1.5m0.44% 0.44% NewShares held: Q3 2023 —, Q4 2023 0, Q1 2024 0, Q2 2024 150.0k
42 PRAXIS PRECISION MEDICINES I COM NEW PRAX PRAX 29,259 $1.2m0.36% 0.36% AddedShares held: Q3 2023 —, Q4 2023 0, Q1 2024 26.9k, Q2 2024 29.3k +2.4k +2,366 8.8%

Sold out since Q1 2024

SecurityTickerShares held beforeValue then
ELI LILLY & CO LLY LLY 15,067 $11.7m15.1k shares
TARSUS PHARMACEUTICALS INC TARS TARS 222,253 $8.1m222.3k shares
TOURMALINE BIO INC TRML TRML 274,219 $6.3m274.2k shares
ANAPTYSBIO INC ANAB ANAB 269,548 $6.1m269.5k shares
SOLENO THERAPEUTICS INC SLNO SLNO 115,833 $5.0m115.8k shares
ACELYRIN INC 714,773 $4.8m714.8k shares
MOONLAKE IMMUNOTHERAPEUTICS MLTX MLTX 90,647 $4.6m90.6k shares
ANNEXON INC ANNX ANNX 605,117 $4.3m605.1k shares
AVADEL PHARMACEUTICALS PLC AVDL AVDL 223,660 $3.8m223.7k shares
DISC MEDICINE INC IRON IRON 60,129 $3.7m60.1k shares
TAYSHA GENE THERAPIES INC TSHA TSHA 1,087,785 $3.1m1.1m shares
ASTRIA THERAPEUTICS INC CATB CATB 230,273 $2.7m230.3k shares
EFFECTOR THERAPEUTICS INC EFTR EFTR 132,793 $1.9m132.8k shares
NEWAMSTERDAM PHARMA COMPANY NAMS NAMS 80,334 $1.9m80.3k shares
CG ONCOLOGY INC CGON CGON 40,723 $1.8m40.7k shares
ACHILLES THERAPEUTICS PLC 1,385,750 $1.7m1.4m shares
DIANTHUS THERAPEUTICS INC DNTH DNTH 43,456 $1.3m43.5k shares
CARGO THERAPEUTICS INC 51,126 $1.1m51.1k shares
KYVERNA THERAPEUTICS INC KYTX KYTX 41,000 $1.0m41.0k shares

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
ARCUTIS BIOTHERAPEUTICS INC ARQT · Call ARQTCall 500,000 $350.0k500.0k shares New

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
CELLECTAR BIOSCIENCES INC CLRB · 13G · filed 2026-08-14 CLRB 9.9%≈ $2.4m new 13G 2026-08-14
XILIO THERAPEUTICS INC XLO · 13G · filed 2026-08-14 XLO 9.5%≈ $5.8m 13G 2026-08-14
XILIO THERAPEUTICS INC 13G · filed 2026-02-17 8.4% +1.2 pts 13G 2026-02-17
SURROZEN INC SRZN · 13G · filed 2026-08-14 SRZN 5.0%≈ $15.6m +0.5 pts 13G 2026-08-14